Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announces revenue of 6.8 million...

New site-specific conjugation technology for homogenous antibody-drug conjugates (ADCs) Provides further opportunities for portfolio expansion and partnering Innate Pharma SA (the “Company” - Euronext...

Nicolai Wagtmann, previously Vice-President R&D at Novo Nordisk A/S, generated and developed a portfolio of therapeutic antibodies for the treatment of cancer and inflammatory diseases François...

• Stable financial results with maintenance of the cash horizon into mid-2015 • Clinical and pre-clinical programs progressing on track • Strengthening of the Supervisory board and of the Scientific...

All proposed resolutions were voted according to management’s recommendations Pr. Michael Caligiuri was appointed as a new member of the Supervisory Board Innate Pharma (Euronext Paris: FR0010331421 –...

Innate Pharma (Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on June 28, 2013, at 9:30 am in its headquarters, 117 avenue de Luminy, F-13009...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces revenue of 2.7...

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces today that new preclinical data for...

Three clinical trials initiated with anti-KIR antibody lirilumab (IPH2102/BMS-986015), including a Phase II trial IPH2201/NN8765 Phase I clinical trial enrolling patients IPH33 drug candidate selected...

Revenue of 14.3 million euros including payments from Bristol-Myers Squibb and research tax credit Strong cash position with 32.6 million euros in cash, cash equivalents and current financial...